Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
α-synuclein—Less Is More?
8 October 2002. Mutations in the gene for α-synuclein are known to cause early-onset, familial forms of Parkinson's disease (PD), and the protein has been found in inclusions in other neurodegenerative diseases such as Alzheimer's. Although it is thought to be involved in neuronal plasticity, the precise function of α-synuclein has remained elusive. Now, in today's PNAS early edition, researchers report that transgenic mice devoid of the protein are resistant to MPTP, a neurotoxin that induces PD like symptoms.

MPTP, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, is a protoxin that crosses the blood brain barrier and is converted by enzymes such as monoamine oxidase to the active 1-methyl-4-phenylpridinium (MPP+), which poisons mitochondria and precipitates a collapse of oxidative respiration. Before it can access the organelles MPP+ must be transported across the cell membranes by specific transporters, in particular the DA transporter, which is found in the dopamine neurons of the substantia nigra, that part of the brain most damaged in Parkinson's sufferers. It is this selective delivery of MPP+ to the dopaminergic neurons that makes MPTP toxicity a useful model for PD.

William Dauer, working with principal author Rene Hen at Columbia University and collaborators at New York State Psychiatric Institute and Harvard Medical School, Boston, tested α-synuclein-null mice with the protoxin. In contrast to wildtype mice, which suffered a substantial loss of dopamine-producing cells in the substantia nigra when subjected to either chronic or acute exposure regimens, the null mice were unaffected. Dauer et al. then tried to determine what particular stage of the toxic pathway is mediated by α-synuclein. They showed that MPTP reaches the striatum in the transgenics, so access across the blood brain barrier is not prevented. They also showed that levels of the DA transporter were normal in the null mice, predicting that MPP+ should be able to penetrate their dopaminergic neurons. However, the authors showed that MPP+ has no effect on primary neuronal cultures from null mice, whereas rotenone, another mitochondrial poison, leads to cell death.

Rotenone and MPP+ are both inhibitors of mitochondrial complex I. The data suggest that the loss of α-synuclein somehow prevents MPP+ from accessing this complex. How this happens is unclear, but the fact that MPTP-induced dopamine efflux, which occurs in wildtype mice, is absent from the null mice is interesting given the intricate relationship that seems to be emerging between the neurotransmitter and the protein (see related news item and item). But as amphetamine-induced efflux of dopamine is normal in the transgenic mice, the authors predict that DA transporter function is uncompromised.

As is often the case with new findings, this paper raises more questions than it answers. It does show, though, how changes in the steady state of a single protein can profoundly increase the susceptibility to damaging environmental factors. -Tom Fagan

Reference:Dauer W, Kholodilov N, Vila M, Trillat A-C, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R. Resistance of a-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14524-9. (Abstract)

 
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad